Diversatek Healthcare Announces the Commercial Release of MiVu™, First GERD Testing Tool to Detect Esophageal Mucosal Changes Instantly, During Routine Endoscopy

MILWAUKEE, Dec. 2, 2020 /PRNewswire/ -- MiVu™, a first-ever mucosal integrity (MI) testing system from Diversatek Healthcare, was granted De Novo classification* from the Food and Drug Administration (FDA) for the safety and efficacy in obtaining measurements of electrical properties within esophageal tissue. MiVu is the only system available to clinicians that provides real-time data of mucosal integrity during routine endoscopy, indicating the existence or probability of gastroesophageal reflux disease (GERD) and other esophageal pathologies in just two minutes.

Diversatek Healthcare, in conjunction with Vanderbilt University, developed the MiVu Mucosal Integrity Testing System to detect changes in esophageal mucosal integrity simply and efficiently. MiVu utilizes a balloon probe and proprietary software to measure conductivity of the esophageal epithelium directly, while providing clinicians both a color contour map and predictive probability. Its unique design, incorporating both radial and axial impedance sensors, measures mucosal integrity at 180-degree intervals along a 10 cm segment of the esophagus, reducing measurement variability. MiVu enables clinicians to quickly and efficiently rule out GERD, differentiate primary esophageal disorders like GERD and eosinophilic esophagitis (EoE), and monitor treatment response. It may eliminate the need for ambulatory reflux testing and multiple invasive biopsies.

"There is a lot of symptom overlap between GERD and EoE, said Dr. Michael Vaezi, Professor of Medicine and Otolaryngology at the Vanderbilt University Medical Center in the Division of Gastroenterology, Hepatology and Nutrition. Current diagnostic tests for esophageal disorders, which are often inconclusive, make it challenging to provide patients with reliable, timely information that adequately guides next steps. MiVu's direct measurement provides accurate, instant data that can immediately direct therapy while helping to reduce the need for unnecessary testing."

"After more than eight years of ongoing testing and clinical studies, we are thrilled to bring MiVu to the market," said Diversatek Healthcare's Chairman Brant Stanford. "Current diagnostic tools for patients experiencing chronic esophageal disorders are incapable of detecting subtle, but real, disease conditions. MiVu is a fast, effective alternative that helps guide therapy decisions and monitors disease activity over time, ultimately saving patients time and money."

To learn more about MiVu, please visit https://www.diversatekhealthcare.com/mucosal-integrity-mivu-2/.

* Class II, Order DEN180067     

About Diversatek Healthcare
Headquartered in Milwaukee, Wisconsin, Diversatek Healthcare is a wholly owned subsidiary of Diversatek Inc. A leader in gastroenterological medical devices and diagnostic tools, Diversatek Healthcare's tenured management team is committed to making business personal again through a hands-on approach to understanding clinical and patient needs. Diversatek Healthcare is driving science in the GI space while providing comprehensive educational offerings through Diversatek University, including on-site training and virtual platforms. The company offers an extensive range of state-of-the-art diagnostic and therapeutic GI applications from esophageal dilators and endoscopic accessories to high resolution impedance manometry systems and impedance/pH total reflux monitoring. For additional information, visit www.diversatekhealthcare.com or contact us at 800-558-6408.

SOURCE Diversatek Healthcare

Related Links

https://www.diversatekhealthcare.com/mucosal-integrity-mivu-2/